

# DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

ATTORNEY DOCKET NO.  
**P1544**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Enhanced Integrated Data Delivery System

the specification of which (check one) ☒ is attached hereto.

\_\_\_\_\_ was filed on \_\_\_\_\_

\_\_\_\_\_ Application Serial No. \_\_\_\_\_

\_\_\_\_\_ and was amended on \_\_\_\_\_  
(if applicable)

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, s 1.56 (a). In the case that the present application is a continuation-in-part application, I further acknowledge the duty to disclose material information as defined in 37 CFR s 1.56(a) which became available between the filing date of the prior application and the filing date of the present application.

I hereby claim foreign priority benefits under Title 35, United States Code s119 of any foreign applications for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

(Number)	(Country)	(Day/Month/Year Filed)
_____	_____	_____
_____	_____	_____

I hereby claim the benefit under Title 35, United States Code, s120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, s112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, s156(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

(List name and registration number)

Donald R. Boys  
Reg. No. 35,074

Joseph H. Smith  
Reg. No. 30,328

SEND CORRESPONDENCE TO:

DIRECT TELEPHONE CALLS TO:

Donald R. Boys  
P.O. Box 187  
Aromas, CA 95004

Donald R. Boys  
(408) 726-1457

FILED 2020 SEP 15 11 11 AM '20

Figure 1 consists of 11 sub-graphs, labeled (a) through (k), each showing a time course of a different physiological or behavioral parameter over a 10-minute period. The x-axis for all graphs represents time in minutes, with a baseline period before the 10-minute intervention. The y-axis scales are specific to each parameter.

- (a) Heart rate (b/min): Shows a slight increase from approximately 70 to 75 b/min during the intervention.
- (b) Blood pressure (mmHg): Shows a slight decrease from approximately 120 to 115 mmHg during the intervention.
- (c) Blood flow (ml/min): Shows a significant increase from approximately 100 to 150 ml/min during the intervention.
- (d) Blood flow (ml/min): Shows a significant increase from approximately 100 to 150 ml/min during the intervention.
- (e) Blood flow (ml/min): Shows a significant increase from approximately 100 to 150 ml/min during the intervention.
- (f) Blood flow (ml/min): Shows a significant increase from approximately 100 to 150 ml/min during the intervention.
- (g) Blood flow (ml/min): Shows a significant increase from approximately 100 to 150 ml/min during the intervention.
- (h) Blood flow (ml/min): Shows a significant increase from approximately 100 to 150 ml/min during the intervention.
- (i) Blood flow (ml/min): Shows a significant increase from approximately 100 to 150 ml/min during the intervention.
- (j) Blood flow (ml/min): Shows a significant increase from approximately 100 to 150 ml/min during the intervention.
- (k) Blood flow (ml/min): Shows a significant increase from approximately 100 to 150 ml/min during the intervention.

Full name of 7th joint inventor, if any \_\_\_\_\_

7th inventor's signature \_\_\_\_\_ Dated: \_\_\_\_\_

Residence \_\_\_\_\_ Citizenship \_\_\_\_\_

Post Office Address \_\_\_\_\_